O
Oncare | Cancer Center Viaducto - Ciudad de Mexico, Mexico
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Tarlatamab
Durvalumab
Platinum
Etoposide
Lurbinectedin
Topotecan
Amrubicin
Parent organization
This site is a part of Oncare
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 3 total trials
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS...
Enrolling
Small-Cell Lung Cancer
Extensive-Stage Small-Cell Lung Cancer
Drug: Tarlatamab
Drug: Durvalumab
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Active, not recruiting
Small Cell Lung Cancer (SCLC)
Drug: Topotecan
Drug: Amrubicin
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).
Enrolling
Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Drug: Placebo
Drug: Tarlatamab
Trial sponsors
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems